Paul Bhatt

Paul Bhatt has been instrumental in the clinical development of mogamulizumab, a CCR4-targeting antibody that depletes Tregs and has demonstrated clinical activity in cutaneous T cell lymphoma and is being evaluated for depletion of tumor-infiltrating Tregs. His research characterized CCR4 expression on tumor-infiltrating Tregs and peripheral Tregs in cancer patients. He has conducted trials examining mogamulizumab as a combination partner with checkpoint inhibitors to deplete Tregs and enhance antitumor immunity. His work has provided important clinical validation that Treg depletion can be achieved safely and combined with immunotherapy.